Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis And Market Forecasts To 2016

The global idiopathic pulmonary fibrosis (IPF) market was valued at $84m in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 25.1% from $84m in 2009 to $348m by 2016. Earlier the IPF market was underserved due to a lack of approved products. In October 2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under regulatory review for approval in the US and the EU. The expected increase in sales is due to the expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the anticipated approval of Letiaris and Tracleer. Gilead’s Letiaris and Actelion’s Tracleer are the most anticipated molecules in the IPF market.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ reportstore/ Report.aspx?ID=Idiopathic-Pulmonary-Fibrosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare

GlobalData found that the current competition in the IPF market is weak due to the unavailability of products for treatment of the disease. There is only one product approved for the treatment of IPF. Shionogi’s Pirespa got approved in 2008 in Japan for the treatment of IPF. Prior to the approval of Pirespa, the market had no approved products. The market was dominated by the off-label use of corticosteroids and immunosuppresants. The minimal efficacy and safety of off-label drugs and the poor response rates exhibited by patients demonstrate the huge unmet need existing in the market.

GlobalData has found that there are over 40 molecules in the various stages of the pipeline. Tracleer and Letiaris are some of the late stage pipeline molecules. Enbrel and Veldona in Phase II are also showing promising activity in treating IPF. These pipeline molecules differ in their targets of action from the existing therapies. All these molecules are already approved for other indications and are in clinical trials for IPF. Tracleer and Letiaris are approved for pulmonary arterial hypertension. Enbrel is already an approved biologic for other indications. Hence, the probable approval of these molecules shows that there is a strong pipeline for IPF. However, IPF is an orphan disease and all these drugs in the pipeline have orphan drug status. Thus, the launch of potential molecules can be expected in the near future.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ reportstore/ Report.aspx?ID=Idiopathic-Pulmonary-Fibrosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare

GlobalData has found that there is a lack of available treatment options in the IPF market. There is no approved drug available to IPF patients outside Japan. The market has only off-label drugs as pharmacological therapy for patients. A poor response rate and minimal safety and efficacy has led to low patient compliance and physican satisfaction towards these treatments. Although it has fewer survival benefits than the other treatments, lung transplantation appears to be the only option available for patients with end-stage idiopathic pulmonary fibrosis. Thus, the lack of available options has led to a weak market.

GlobalData’s report, “Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global idiopathic pulmonary fibrosis (IPF) market. The report identifies the key trends shaping and driving the global IPF market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global IPF sector.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ reportstore/ Report.aspx?ID=Idiopathic-Pulmonary-Fibrosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Or visit our report store: http://www.globaldata.com/ reportstore

User comments, Ratings and Reviews

News Reviews and Ratings

Be the first person to review this news article. By reviewing the news article you are automatically sent to our Online Sweepstakes and any questions on journal postings and more info from here

News Album Team, Wednesday, June 19, 2013 12:43:08 AM

Note: To write new journal then start here. The below is only to re-write the existing journal
Write your own Review on This News: Start Your Journal :

Name Email Required valid email. Confirmation sent here.
News I would care : Not Much. 1 2 3 4 5 So Much......!

Verification code Human Verification Code

Read more! [Bookmark & read later / Comment this story ]

Share this article:

You can Digg this article:
Send Page to Friend(s):
Bookmark with del.icio.us:

Cast My Opinion

Contact Author: Click here to eMail

Rajesh Gunnam from 220.225.231.xxx

Article Taged as : idiopathic, pulmonary, fibrosis, drug, pipeline, analysis, market, forecasts, 2016, http, www.globaldata.com, idiopathic, pulmonary, fibrosis, drug, pipeline, analysis, market, forecasts, 2016,

Article Statistics

Article Viewed 4819 times.
Positive attitude 1 votes [0%]
Negetive attitude 1 votes [0%]

News Article Source & Groups

You can find this article under group. And brought to you by Channel ,
The XMl Feed Type and collected data bytes sized news and still counting.
Feed Server name is and Code Page (Not Defined/Un Known)

: : Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016
Date Listed : Wednesday, March 17, 2010
Source : ,

Related Stories

A2LA Announces Crime Scene Analysis Accreditation Pilot Program

A2LA Pilot Program is being offered in the area of crime scene analysis(PRWeb February 17, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9206942.htm

Collabera and Panopticon to Jointly Develop New Visual Data Analysis Solutions for Financial and Telecommunications Customers in US and UK

The two organizations have signed a partnership agreement that will allow Collabera to embed Panopticon’s data visualization tools into its comprehensive data analysis and business intelligence solutions. (PRWeb Jun 22, ...

Here We Grow Again Internet Marketing Firm Conversion Pipeline Opens New Office in Williamsburg Virginia

Small business Internet marketing specialist, Conversion Pipeline, announces that it is expanding its operations with opening an office in Williamsburg, Virginia. (PRWeb Jun 22, 2010) ...

Lead Generation Marketing ROI Study Released

Survey Reveals Opportunities to Increase B2B Lead Generation Performance and Profitability. (PRWeb Jun 21, 2010) Read the full story at http://www.prweb.com/releases/2010/06/prweb3426094.htm

Many clinicians maintain positive attitudes toward industry marketing activities

Despite current policy trends, many clinicians continue to hold positive attitudes toward gifts from and marketing interactions with pharmaceutical and device companies, according to a new study.

Bacteria in the nose and throat Most comprehensive comparative analysis

Scientists have completed the most comprehensive comparative analysis to date of bacterial communities inhabiting the human nose and throat, which could provide new insights into why some individuals become colonized ...

Multivariate SPC and Stability Analysis Shelf Life Prediction Featured in NWA Quality Analyst� Version 6.2

Northwest Analytical, Inc. introduces the next generation of Quality Analytics with NWA Quality Analyst® Version 6.2 which provides improved performance, new tools for breaking down data, and two ...

eInserts A Cost Effective Alternative to Email Marketing

eInserts.net announces a cost effective alternative to email marketing that promises to deliver real value as well as measurable results. (PRWeb Apr 2, 2010) ...

invivodata Offers Complimentary PRO Gap Analysis

Patient Reported Outcome analysis and deeper insight into FDA Final Guidance (PRWeb Mar 25, 2010) Read the full story at http://www.prweb.com/releases/2010/03/prweb3772134.htm

Peruvian Amazon trees a niche market for carbon trading AFP

AFP - In a far-flung corner of the Peruvian Amazon, a multinational company aims to offset carbon dioxide emissions from its factories in France by planting thousands of trees which ...

Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016

Today's Cartoon